GlassScriptPhysician profile
Heather Welch
NPI 1063423291
$2,813.87
in general payments reported to CMS, 2019-2025
25 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $807 · 2022: $702 · 2023: $288 · 2024: $501 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.09 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $376.82 | 2021-2023 | |
| Astellas Pharma US INC | $226.50 | 2024-2025 | Veozah |
| Exeltis, USA INC. | $224.76 | 2021-2025 | Slynd |
| Mayne Pharma Commercial LLC | $205.65 | 2021-2025 | |
| Intra-Sana Laboratories | $199.46 | 2023-2025 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Bausch Health US, LLC | $167.53 | 2021-2023 | Aplenzin, Wellbutrin |
| Currax Pharmaceuticals LLC | $163.82 | 2021-2025 | Contrave |
| Exact Sciences Corporation | $121.04 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $111.80 | 2021-2024 | |
| Novo Nordisk INC | $110.69 | 2021-2024 | Wegovy |
| Myovant Sciences INC. | $106.24 | 2021-2022 | |
| Therapeuticsmd, INC. | $105.78 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.02 | 2021-2025 | |
| Millicent US INC | $87.50 | 2022-2025 | Intrarosa, Femring, Femlyv |
| Organon LLC | $70.91 | 2021-2023 | Nexplanon |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $70.14 | 2022 | |
| Mylan Pharmaceuticals INC. | $67.14 | 2021-2022 | |
| Lilly USA, LLC | $64.28 | 2024-2025 | Zepbound, Mounjaro |
| Agile Therapeutics, INC. | $63.31 | 2021-2022 | |
| Hologic Sales and Service, LLC | $57.16 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Coopersurgical, INC. | $32.56 | 2021-2025 | Paragard T 380a |
| Evofem Biosciences, INC. | $32.00 | 2022 | |
| Sumitomo Pharma America, INC. | $17.02 | 2023 | Myfembree |
| Mycovia Pharmaceuticals, INC. | $16.27 | 2022 | |
| Biogen, INC. | $15.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Welch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.